Tyra Biosciences Inc (TYRA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.38B
Last updated: Nov 17, 2026 at 11:06 AM ET
Tyra Biosciences Inc (TYRA) Stock Forecast
Analysts expect Tyra Biosciences (TYRA) to earn -$2.70 per share in the fiscal year ending Dec 31, 2026. Of 15 analysts, 14 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 1.93, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 13.3% |
| Buy | 12 | 80.0% |
| Hold | 1 | 6.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$2.70
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$2.81
- EPS consensus
- Next report
- Mar 1, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.70 | -$2.86 to -$2.35 | 13 |
| Dec 31, 2027 | -$2.81 | -$3.36 to -$2.23 | 14 |
Quarterly Estimates
The EPS consensus rises from -$0.72 for the quarter ending Dec 31, 2026 to -$0.67 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.72 | -$0.77 to -$0.59 | 17 |
| Mar 31, 2027 | -$0.67 | -$0.80 to -$0.51 | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 12 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 0 |
| Fiscal year ending Dec 31, 2027 | 5 | 0 |
| Quarter ending Mar 31, 2027 | 3 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.67.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.70 | -$2.64 | -$2.64 | -$2.66 | -$2.67 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.81 | -$2.77 | -$2.77 | -$2.88 | -$2.96 | N/A |
| Quarter ending Mar 31, 2027 | -$0.67 | -$0.64 | -$0.64 | -$0.69 | -$0.74 | N/A |
Frequently Asked Questions About TYRA
What is the TYRA stock forecast?
Consensus analyst estimates put Tyra Biosciences's EPS at -$2.70 for the fiscal year ending Dec 31, 2026. The consensus rating from 15 analysts is Buy.
How do analysts rate TYRA stock?
Of 15 analysts covering Tyra Biosciences, 2 rate it Strong Buy, 12 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TYRA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.70, with estimates from -$2.86 to -$2.35 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.81, with estimates from -$3.36 to -$2.23 from 14 analysts.
How many analysts cover TYRA?
15 analysts rate Tyra Biosciences stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TYRA pages: Overview, Earnings, Forecast, Financials, Competitors